By Inti Landauro
PARIS--Valeant Pharmaceuticals International Inc. (VRX.T) is to
buy the U.S. ophthalmic diagnostics unit of French biotech firm
Nicox SA (COX.FR) for up to $20 million, the French firm said
Monday in a statement.
According to the deal reached by the two companies, Valeant will
pay Nicox $10 million in cash and up to $10 million in several
installments if sales-based milestones are reached, Nicox said.
The acquisition comes as Valeant is pushing to buy Allergan, the
maker of Botox, in a deal worth more than $50 million.
Write to Inti Landauro at inti.landauro@wsj.com
Access Investor Kit for Valeant Pharmaceuticals International,
Inc.
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=CA91911K1021
Access Investor Kit for Nicox SA
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=FR0000074130
Subscribe to WSJ: http://online.wsj.com?mod=djnwires